WO2008087882A1 - 胃内滞留型レボドパ徐放性製剤 - Google Patents

胃内滞留型レボドパ徐放性製剤 Download PDF

Info

Publication number
WO2008087882A1
WO2008087882A1 PCT/JP2008/050159 JP2008050159W WO2008087882A1 WO 2008087882 A1 WO2008087882 A1 WO 2008087882A1 JP 2008050159 W JP2008050159 W JP 2008050159W WO 2008087882 A1 WO2008087882 A1 WO 2008087882A1
Authority
WO
WIPO (PCT)
Prior art keywords
levodopa
sustained
intragastric floating
floating
type
Prior art date
Application number
PCT/JP2008/050159
Other languages
English (en)
French (fr)
Inventor
Denichi Momose
Nobuyuki Isshiki
Noboru Kamada
Original Assignee
Kissei Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co., Ltd. filed Critical Kissei Pharmaceutical Co., Ltd.
Priority to EP08703030A priority Critical patent/EP2105133A1/en
Priority to JP2008554012A priority patent/JPWO2008087882A1/ja
Priority to US12/523,117 priority patent/US20100112053A1/en
Priority to CA002673485A priority patent/CA2673485A1/en
Publication of WO2008087882A1 publication Critical patent/WO2008087882A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)

Abstract

　本発明は、レボドパの持続的な血中濃度の維持を目的として、レボドパを胃内で持続的に放出することができ十分な胃内滞留時間を有する、服用しやすい大きさのレボドパ製剤であって、しかも工業的に製造しやすいレボドパ製剤を提供することを課題とする。レボドパを含む薬物放出層に加え、胃内においては高い機械的強度に基づく十分な滞留性を示し、かつ腸管内においては良好な崩壊性を示す胃内滞留層を含むことを特徴とするレボドパ胃内滞留製剤。 
PCT/JP2008/050159 2007-01-15 2008-01-10 胃内滞留型レボドパ徐放性製剤 WO2008087882A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08703030A EP2105133A1 (en) 2007-01-15 2008-01-10 Intragastric floating-type levodopa sustained-release preparation
JP2008554012A JPWO2008087882A1 (ja) 2007-01-15 2008-01-10 胃内滞留型レボドパ徐放性製剤
US12/523,117 US20100112053A1 (en) 2007-01-15 2008-01-10 Gastric retention-type sustained-release levodopa preparation
CA002673485A CA2673485A1 (en) 2007-01-15 2008-01-10 Gastric retention-type sustained-release levodopa preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007005438 2007-01-15
JP2007-005438 2007-01-15

Publications (1)

Publication Number Publication Date
WO2008087882A1 true WO2008087882A1 (ja) 2008-07-24

Family

ID=39635886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/050159 WO2008087882A1 (ja) 2007-01-15 2008-01-10 胃内滞留型レボドパ徐放性製剤

Country Status (5)

Country Link
US (1) US20100112053A1 (ja)
EP (1) EP2105133A1 (ja)
JP (1) JPWO2008087882A1 (ja)
CA (1) CA2673485A1 (ja)
WO (1) WO2008087882A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008280251A (ja) * 2007-05-08 2008-11-20 Shin Etsu Chem Co Ltd 多層錠及びその製造方法
WO2010019915A1 (en) * 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
JP2019523305A (ja) * 2016-07-29 2019-08-22 ソム イノベーション バイオテク エス．エル．Ｓｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ，Ｓ．Ｌ． 微粒子化トルカポンを含む徐放性錠剤
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5718937B2 (ja) * 2009-12-25 2015-05-13 イノファーマックス インコーポレイテッド パーキンソン病を治療するための医薬組成物及びその調製方法
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
EP2893928B1 (en) 2012-09-03 2018-10-24 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
US10485758B2 (en) 2014-06-02 2019-11-26 Clexio Biosciences Ltd. Expandable gastroretentive dosage form
US10737079B2 (en) 2016-12-02 2020-08-11 Clexio Biosciences Ltd. Gastric residence system
US10918597B2 (en) 2017-06-16 2021-02-16 Kashiv Specialty Pharmaceuticals, Llc Gastroretentive dosage forms for sustained drug delivery
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
JP7296084B2 (ja) 2017-12-04 2023-06-22 クレキシオ バイオサイエンシーズ エルティーディー． 長時間作用型胃滞留システム
EP4056172A1 (en) 2018-06-18 2022-09-14 Amneal Complex Products Research LLC Extended release compositions comprising pyridostigmine
IT202100006776A1 (it) * 2021-03-22 2022-09-22 Univ Degli Studi Genova Metodo di produzione di matrici compatte gastroritentive per il rilascio controllato di sostanze attive e matrici compatte così ottenute

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006281A1 (en) * 1989-10-26 1991-05-16 Nippon Shinyaku Co., Ltd. Gastric preparation
JPH0667830B2 (ja) 1987-12-11 1994-08-31 メルク エンド カムパニーインコーポレーテツド カルビドパ／レボドパの制御放出配合剤
JPH07247222A (ja) * 1994-03-11 1995-09-26 Tanabe Seiyaku Co Ltd 消化管内適所放出型製剤
WO1999007342A1 (en) 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
WO2000015197A1 (en) 1998-09-14 2000-03-23 Rubin Alan A Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
WO2002000213A1 (en) 2000-06-23 2002-01-03 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
WO2004032906A1 (en) 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
JP2005132803A (ja) 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
JP2006523633A (ja) * 2003-04-18 2006-10-19 ユニハート　コーポレーション レボドーパ及びカルビドーパを含む医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
KR20070036797A (ko) * 2004-07-26 2007-04-03 테바 파마슈티컬 인더스트리즈 리미티드 장용 코팅된 중심정을 갖는 제형

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0667830B2 (ja) 1987-12-11 1994-08-31 メルク エンド カムパニーインコーポレーテツド カルビドパ／レボドパの制御放出配合剤
WO1991006281A1 (en) * 1989-10-26 1991-05-16 Nippon Shinyaku Co., Ltd. Gastric preparation
JPH07247222A (ja) * 1994-03-11 1995-09-26 Tanabe Seiyaku Co Ltd 消化管内適所放出型製剤
WO1999007342A1 (en) 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
WO2000015197A1 (en) 1998-09-14 2000-03-23 Rubin Alan A Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
WO2002000213A1 (en) 2000-06-23 2002-01-03 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
WO2004032906A1 (en) 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
JP2006523633A (ja) * 2003-04-18 2006-10-19 ユニハート　コーポレーション レボドーパ及びカルビドーパを含む医薬組成物
JP2005132803A (ja) 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KLAUSNER, E. A. ET AL., PHARMACEUTICAL RESEARCH, vol. 20, no. 9, 2003, pages 1466 - 1473

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008280251A (ja) * 2007-05-08 2008-11-20 Shin Etsu Chem Co Ltd 多層錠及びその製造方法
WO2010019915A1 (en) * 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
JP2012500221A (ja) * 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
US9161911B2 (en) 2008-08-15 2015-10-20 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
US9566258B2 (en) 2008-08-15 2017-02-14 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
US9937142B2 (en) 2008-08-15 2018-04-10 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
JP2019523305A (ja) * 2016-07-29 2019-08-22 ソム イノベーション バイオテク エス．エル．Ｓｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ，Ｓ．Ｌ． 微粒子化トルカポンを含む徐放性錠剤
JP7047236B2 (ja) 2016-07-29 2022-04-05 ソム イノベーション バイオテク ソシエダッド アノニマ 微粒子化トルカポンを含む徐放性錠剤
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US11389398B2 (en) 2019-05-14 2022-07-19 Clexio Biosciences Ltd. Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Also Published As

Publication number Publication date
JPWO2008087882A1 (ja) 2010-05-06
EP2105133A1 (en) 2009-09-30
CA2673485A1 (en) 2008-07-24
US20100112053A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
WO2008087882A1 (ja) 胃内滞留型レボドパ徐放性製剤
WO2010064139A3 (en) Zaleplon gastroretentive drug delivery system
MY151137A (en) Probiotics to improve gut microbiota
EP2364144A4 (en) PHARMACEUTICAL FORM FOR ADMINISTRATION THROUGH THE MOUTH
WO2011048494A3 (en) Novel gastroretentive dosage forms of poorly soluble drugs
WO2011111027A3 (en) Oral dispersible delayed release tablet formulation
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
WO2008058288A3 (en) Sustained release methotrexate formulations and methods of use thereof
WO2007048223A3 (en) A gastric retention drug delivery system
WO2007110866A3 (en) Floating gastrointestinal anchor
SG176687A1 (en) Solid compositions comprising 5-aminolevulinic acid
WO2007092390A3 (en) Devices and methods for gastrointestinal stimulation
JP2010535767A5 (ja)
AR062583A1 (es) Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
EP1980272A3 (en) Orally-disintegrating tablet and manufacturing method thereof
WO2011009848A3 (en) Therapeutic use of probiotics
WO2012010669A3 (de) Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
WO2007059490A3 (en) Gastro-intestinal therapeutic device and method
EP2029146B8 (en) Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
PL382831A1 (pl) Preparat stanowiący dodatek paszowy zawierający mieszaninę maślanu sodu i kwasów organicznych oraz wyciągu z Yucca Schidigeri i zastosowanie preparatu do wytwarzania środka leczniczego do leczenia wspomagającego układ pokarmowy
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2007120848A3 (en) Devices, systems and methods using magnetic force systems in the tongue
WO2011083402A3 (en) Immediate release compositions of acid labile drugs
WO2006047799A3 (en) Treatment of heart failure with csf-1
MX2007003916A (es) Gastroplastia amoldable: dispositivos y metodos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08703030

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008554012

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2673485

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12523117

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008703030

Country of ref document: EP